ParkinsonFranceV1, Istex, Corpus, bibRecord, 000D66

Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase

Identifieur interne : 000D66 ( Istex/Corpus ); précédent : 000D65; suivant : 000D67

Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase

Auteurs : M. Strolin Benedetti ; P. Dostert

Source :

Trends in Pharmacological Sciences [ 0165-6147 ] ; 1985.

RBID : ISTEX:94EE8E5214CEF87B591F3008F7BAD5244013C9AE

Abstract

Monoamine oxidase inhibitors have for a long time received ’bad press’. However, the new selective and reversible MAOIs are associated with considerably reduced risk of untoward side-effects. Margherita Strolin Benedetti and Philippe Dostert review the chemistry and pharmacology of these compounds and describe the roles of functional groups and the asymmetric centres of substrates and reversible MAOIs in differential recognition by the A or B forms of MAO.

Url:

https://api.istex.fr/document/94EE8E5214CEF87B591F3008F7BAD5244013C9AE/fulltext/pdf

DOI: 10.1016/0165-6147(85)90116-6

Links to Exploration step

ISTEX:94EE8E5214CEF87B591F3008F7BAD5244013C9AE

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</title>
<author><name sortKey="Benedetti, M Strolin" sort="Benedetti, M Strolin" uniqKey="Benedetti M" first="M. Strolin" last="Benedetti">M. Strolin Benedetti</name>
<affiliation><mods:affiliation>Department of Biochemical and Clinical Pharmacology, Fournier Laboratories, 21121, Dijon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dostert, P" sort="Dostert, P" uniqKey="Dostert P" first="P." last="Dostert">P. Dostert</name>
<affiliation><mods:affiliation>Research Centre, Fournier Laboratories, 21121, Dijon, France</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:94EE8E5214CEF87B591F3008F7BAD5244013C9AE</idno>
<date when="1985" year="1985">1985</date>
<idno type="doi">10.1016/0165-6147(85)90116-6</idno>
<idno type="url">https://api.istex.fr/document/94EE8E5214CEF87B591F3008F7BAD5244013C9AE/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000D66</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</title>
<author><name sortKey="Benedetti, M Strolin" sort="Benedetti, M Strolin" uniqKey="Benedetti M" first="M. Strolin" last="Benedetti">M. Strolin Benedetti</name>
<affiliation><mods:affiliation>Department of Biochemical and Clinical Pharmacology, Fournier Laboratories, 21121, Dijon, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dostert, P" sort="Dostert, P" uniqKey="Dostert P" first="P." last="Dostert">P. Dostert</name>
<affiliation><mods:affiliation>Research Centre, Fournier Laboratories, 21121, Dijon, France</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Trends in Pharmacological Sciences</title>
<title level="j" type="abbrev">TIPS</title>
<idno type="ISSN">0165-6147</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1985">1985</date>
<biblScope unit="volume">6</biblScope>
<biblScope unit="supplement">C</biblScope>
<biblScope unit="page" from="246">246</biblScope>
<biblScope unit="page" to="251">251</biblScope>
</imprint>
<idno type="ISSN">0165-6147</idno>
</series>
<idno type="istex">94EE8E5214CEF87B591F3008F7BAD5244013C9AE</idno>
<idno type="DOI">10.1016/0165-6147(85)90116-6</idno>
<idno type="PII">0165-6147(85)90116-6</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0165-6147</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Monoamine oxidase inhibitors have for a long time received ’bad press’. However, the new selective and reversible MAOIs are associated with considerably reduced risk of untoward side-effects. Margherita Strolin Benedetti and Philippe Dostert review the chemistry and pharmacology of these compounds and describe the roles of functional groups and the asymmetric centres of substrates and reversible MAOIs in differential recognition by the A or B forms of MAO.</div>
</front>
</TEI>
<istex><corpusName>elsevier</corpusName>
<author><json:item><name>M.Strolin Benedetti</name>
<affiliations><json:string>Department of Biochemical and Clinical Pharmacology, Fournier Laboratories, 21121, Dijon, France</json:string>
</affiliations>
</json:item>
<json:item><name>P. Dostert</name>
<affiliations><json:string>Research Centre, Fournier Laboratories, 21121, Dijon, France</json:string>
</affiliations>
</json:item>
</author>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>Full-length article</json:string>
</originalGenre>
<abstract>Monoamine oxidase inhibitors have for a long time received ’bad press’. However, the new selective and reversible MAOIs are associated with considerably reduced risk of untoward side-effects. Margherita Strolin Benedetti and Philippe Dostert review the chemistry and pharmacology of these compounds and describe the roles of functional groups and the asymmetric centres of substrates and reversible MAOIs in differential recognition by the A or B forms of MAO.</abstract>
<qualityIndicators><score>5.816</score>
<pdfVersion>1.2</pdfVersion>
<pdfPageSize>540 x 756 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<keywordCount>0</keywordCount>
<abstractCharCount>460</abstractCharCount>
<pdfWordCount>5449</pdfWordCount>
<pdfCharCount>24273</pdfCharCount>
<pdfPageCount>6</pdfPageCount>
<abstractWordCount>68</abstractWordCount>
</qualityIndicators>
<title>Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</title>
<pii><json:string>0165-6147(85)90116-6</json:string>
</pii>
<refBibs><json:item><host><volume>1</volume>
<pages><last>886</last>
<first>881</first>
</pages>
<author></author>
<title>Br. Med. J.</title>
</host>
</json:item>
<json:item><host><volume>17</volume>
<pages><last>1297</last>
<first>1285</first>
</pages>
<author></author>
<title>Biochem. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>25</volume>
<pages><last>2077</last>
<first>2073</first>
</pages>
<author></author>
<title>Biochem. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>174</volume>
<pages><last>36</last>
<first>32</first>
</pages>
<author></author>
<title>Arch. Int. Pharmacodyn. Ther.</title>
</host>
</json:item>
<json:item><host><volume>61</volume>
<pages><last>119P</last>
<first>118P</first>
</pages>
<author></author>
<title>Br. J. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>29</volume>
<pages><last>1183</last>
<first>1177</first>
</pages>
<author></author>
<title>Biochem. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>61</volume>
<pages><last>471P</last>
<first>470P</first>
</pages>
<author></author>
<title>Br. J. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>11</volume>
<pages><last>35</last>
<first>28</first>
</pages>
<author></author>
<title>Mol. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>34</volume>
<pages><last>1260</last>
<first>1258</first>
</pages>
<author></author>
<title>Arzneim. Forsch.</title>
</host>
</json:item>
<json:item><host><pages><last>112</last>
<first>103</first>
</pages>
<author></author>
<title>Monoamine oxidase inhibitors. The state of the art</title>
</host>
</json:item>
<json:item><host><volume>36</volume>
<pages><last>1571</last>
<first>1561</first>
</pages>
<author></author>
<title>J. Neurochem.</title>
</host>
</json:item>
<json:item><host><volume>31</volume>
<pages><last>754</last>
<first>752</first>
</pages>
<author></author>
<title>J. Pharm. Pharmacol.</title>
</host>
</json:item>
<json:item><host><pages><last>245</last>
<first>231</first>
</pages>
<author></author>
<title>Monoamine Oxidase and its selective inhibitors, Modern Problems of Pharmacopsychiatry</title>
</host>
</json:item>
<json:item><host><pages><last>52</last>
<first>31</first>
</pages>
<author></author>
<title>Monoamine Oxidase and its selective inhibitors, Modern Problems of Pharmacopsychiatry</title>
</host>
</json:item>
<json:item><host><pages><last>116</last>
<first>107</first>
</pages>
<author></author>
<title>Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors</title>
</host>
</json:item>
<json:item><host><volume>35</volume>
<pages><last>165</last>
<first>161</first>
</pages>
<author></author>
<title>J. Pharm. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>35</volume>
<pages><last>840</last>
<first>837</first>
</pages>
<author></author>
<title>J. Pharm. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>33</volume>
<pages><last>406</last>
<first>403</first>
</pages>
<author></author>
<title>J. Pharm. Pharmacol.</title>
</host>
</json:item>
<json:item><host><volume>4</volume>
<pages><last>358</last>
<first>323</first>
</pages>
<author></author>
<title>Medical Research Reviews</title>
</host>
</json:item>
<json:item><host><pages><last>584</last>
<first>582</first>
</pages>
<author></author>
<title>Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors</title>
</host>
</json:item>
<json:item><author></author>
<host><author></author>
<title>Abstracts from the Symposium</title>
</host>
<serie><author></author>
<title>Abstracts from the Symposium</title>
</serie>
<title>Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors</title>
</json:item>
<json:item><host><volume>311</volume>
<pages><last>469</last>
<first>467</first>
</pages>
<author></author>
<title>Nature (London)</title>
</host>
</json:item>
<json:item><host><pages><last>441</last>
<first>429</first>
</pages>
<author></author>
<title>Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors</title>
</host>
</json:item>
<json:item><host><volume>107</volume>
<pages><last>838</last>
<first>822</first>
</pages>
<author></author>
<title>Ann. N.Y. Acad. Sci.</title>
</host>
</json:item>
<json:item><host><pages><last>230</last>
<first>219</first>
</pages>
<author></author>
<title>Proceedings of the 9th International Congress of Pharmacology, IUPHAR-London 1984</title>
</host>
</json:item>
</refBibs>
<genre><json:string>research-article</json:string>
</genre>
<serie><language><json:string>unknown</json:string>
</language>
<title>Abstracts from the Symposium</title>
</serie>
<host><volume>6</volume>
<pii><json:string>S0165-6147(00)X0173-3</json:string>
</pii>
<pages><last>251</last>
<first>246</first>
</pages>
<issn><json:string>0165-6147</json:string>
</issn>
<genre><json:string>journal</json:string>
</genre>
<language><json:string>unknown</json:string>
</language>
<title>Trends in Pharmacological Sciences</title>
<publicationDate>1985</publicationDate>
</host>
<categories><wos><json:string>science</json:string>
<json:string>pharmacology & pharmacy</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>pharmacology & pharmacy</json:string>
</scienceMetrix>
</categories>
<publicationDate>1985</publicationDate>
<copyrightDate>1985</copyrightDate>
<doi><json:string>10.1016/0165-6147(85)90116-6</json:string>
</doi>
<id>94EE8E5214CEF87B591F3008F7BAD5244013C9AE</id>
<score>0.16815063</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/94EE8E5214CEF87B591F3008F7BAD5244013C9AE/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/94EE8E5214CEF87B591F3008F7BAD5244013C9AE/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/94EE8E5214CEF87B591F3008F7BAD5244013C9AE/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>ELSEVIER</publisher>
<availability><p>ELSEVIER</p>
</availability>
<date>1985</date>
</publicationStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a">Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</title>
<author xml:id="author-1"><persName><forename type="first">M.Strolin</forename>
<surname>Benedetti</surname>
</persName>
<affiliation>Department of Biochemical and Clinical Pharmacology, Fournier Laboratories, 21121, Dijon, France</affiliation>
</author>
<author xml:id="author-2"><persName><forename type="first">P.</forename>
<surname>Dostert</surname>
</persName>
<affiliation>Research Centre, Fournier Laboratories, 21121, Dijon, France</affiliation>
</author>
</analytic>
<monogr><title level="j">Trends in Pharmacological Sciences</title>
<title level="j" type="abbrev">TIPS</title>
<idno type="pISSN">0165-6147</idno>
<idno type="PII">S0165-6147(00)X0173-3</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1985"></date>
<biblScope unit="volume">6</biblScope>
<biblScope unit="supplement">C</biblScope>
<biblScope unit="page" from="246">246</biblScope>
<biblScope unit="page" to="251">251</biblScope>
</imprint>
</monogr>
<idno type="istex">94EE8E5214CEF87B591F3008F7BAD5244013C9AE</idno>
<idno type="DOI">10.1016/0165-6147(85)90116-6</idno>
<idno type="PII">0165-6147(85)90116-6</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>1985</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Monoamine oxidase inhibitors have for a long time received ’bad press’. However, the new selective and reversible MAOIs are associated with considerably reduced risk of untoward side-effects. Margherita Strolin Benedetti and Philippe Dostert review the chemistry and pharmacology of these compounds and describe the roles of functional groups and the asymmetric centres of substrates and reversible MAOIs in differential recognition by the A or B forms of MAO.</p>
</abstract>
</profileDesc>
<revisionDesc><change when="1985">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/94EE8E5214CEF87B591F3008F7BAD5244013C9AE/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType>
<istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>TIPS</jid>
<aid>85901166</aid>
<ce:pii>0165-6147(85)90116-6</ce:pii>
<ce:doi>10.1016/0165-6147(85)90116-6</ce:doi>
<ce:copyright type="unknown" year="1985"></ce:copyright>
</item-info>
<head><ce:title>Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</ce:title>
<ce:author-group><ce:author><ce:given-name>M.Strolin</ce:given-name>
<ce:surname>Benedetti</ce:surname>
<ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>P.</ce:given-name>
<ce:surname>Dostert</ce:surname>
<ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:affiliation id="AFF1"><ce:label>a</ce:label>
<ce:textfn>Department of Biochemical and Clinical Pharmacology, Fournier Laboratories, 21121, Dijon, France</ce:textfn>
</ce:affiliation>
<ce:affiliation id="AFF2"><ce:label>b</ce:label>
<ce:textfn>Research Centre, Fournier Laboratories, 21121, Dijon, France</ce:textfn>
</ce:affiliation>
</ce:author-group>
<ce:abstract><ce:section-title>Abstract</ce:section-title>
<ce:abstract-sec><ce:simple-para>Monoamine oxidase inhibitors have for a long time received ’bad press’. However, the new selective and reversible MAOIs are associated with considerably reduced risk of untoward side-effects. <ce:italic>Margherita Strolin Benedetti</ce:italic>
 and <ce:italic>Philippe Dostert</ce:italic>
 review the chemistry and pharmacology of these compounds and describe the roles of functional groups and the asymmetric centres of substrates and reversible MAOIs in differential recognition by the A or B forms of MAO.</ce:simple-para>
</ce:abstract-sec>
</ce:abstract>
</head>
</converted-article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo><title>Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA"><title>Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase</title>
</titleInfo>
<name type="personal"><namePart type="given">M.Strolin</namePart>
<namePart type="family">Benedetti</namePart>
<affiliation>Department of Biochemical and Clinical Pharmacology, Fournier Laboratories, 21121, Dijon, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P.</namePart>
<namePart type="family">Dostert</namePart>
<affiliation>Research Centre, Fournier Laboratories, 21121, Dijon, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="Full-length article"></genre>
<originInfo><publisher>ELSEVIER</publisher>
<dateIssued encoding="w3cdtf">1985</dateIssued>
<copyrightDate encoding="w3cdtf">1985</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="en">Monoamine oxidase inhibitors have for a long time received ’bad press’. However, the new selective and reversible MAOIs are associated with considerably reduced risk of untoward side-effects. Margherita Strolin Benedetti and Philippe Dostert review the chemistry and pharmacology of these compounds and describe the roles of functional groups and the asymmetric centres of substrates and reversible MAOIs in differential recognition by the A or B forms of MAO.</abstract>
<relatedItem type="host"><titleInfo><title>Trends in Pharmacological Sciences</title>
</titleInfo>
<titleInfo type="abbreviated"><title>TIPS</title>
</titleInfo>
<genre type="journal">journal</genre>
<originInfo><dateIssued encoding="w3cdtf">1985</dateIssued>
</originInfo>
<identifier type="ISSN">0165-6147</identifier>
<identifier type="PII">S0165-6147(00)X0173-3</identifier>
<part><date>1985</date>
<detail type="volume"><number>6</number>
<caption>vol.</caption>
</detail>
<detail type="supplement"><number>C</number>
<caption>Suppl.</caption>
</detail>
<extent unit="issue pages"><start>S1</start>
<end>S28</end>
</extent>
<extent unit="issue pages"><start>1</start>
<end>491</end>
</extent>
<extent unit="pages"><start>246</start>
<end>251</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">94EE8E5214CEF87B591F3008F7BAD5244013C9AE</identifier>
<identifier type="DOI">10.1016/0165-6147(85)90116-6</identifier>
<identifier type="PII">0165-6147(85)90116-6</identifier>
<recordInfo><recordContentSource>ELSEVIER</recordContentSource>
</recordInfo>
</mods>
</metadata>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D66 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D66 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:94EE8E5214CEF87B591F3008F7BAD5244013C9AE
   |texte=   Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase

Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri